HPV Vaccination of Boys in Primary Care Practices

Allison, Mandy A.; Dunne, Eileen F.; Markowitz, Lauri E.; O’Leary, Sean T.; Crane, Lori A.; Hurley, Laura P.; Stokley, Shannon; Babbel, Christine; Brtnikova, Michaela; Beaty, Brenda; Kempe, Allison

doi:10.1016/j.acap.2013.03.006

Cited by 36 publications

(55 citation statements)

References 39 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,32,37,44,45 In contrast, no studies found a correlation between providers' perceptions of HPV vaccine safety and their recommendation behaviors, perhaps because concerns about safety were relatively uncommon. 27,32,36,38,44,45 In terms of providers' perceptions of themselves, self-efficacy to communicate about HPV vaccine was associated with recommending and intending to recommend the vaccine. 12,26,46 Interestingly, providers who viewed themselves as "early adopters" were also more likely to recommend HPV vaccine.…”

Section: Preferences In Communication Source By Provider Typementioning

confidence: 83%

“…32 Studies of providers with higher participation in Medicaid or the Vaccines for Children program found that this participation was associated with more positive HPV vaccine recommendation practices 9,23,30,[33][34][35] or no effect. 29,44,48 Provider recommendations did not vary substantially by national region, 30,[33][34][35]39,44 but providers practicing in urban areas more often reported recommending HPV vaccine than those in rural or suburban ones. 34,37,44,46 Audience Variation in recommendations by patient factors Studies assessing patient factors associated with receiving an HPV vaccine recommendation most often examined patient demographics and providers' perceptions of patients' risk of HPV infection.…”

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

“…29,44,48 Provider recommendations did not vary substantially by national region, 30,[33][34][35]39,44 but providers practicing in urban areas more often reported recommending HPV vaccine than those in rural or suburban ones. 34,37,44,46 Audience Variation in recommendations by patient factors Studies assessing patient factors associated with receiving an HPV vaccine recommendation most often examined patient demographics and providers' perceptions of patients' risk of HPV infection. A consistent finding for adolescent patients was that providers' recommendation intentions and behavior improved with patient age, such that recommendations were stronger and more frequent for older adolescents than for those in the target age range of 11-12 years old.…”

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

“…12,32 Other studies failed to find variation in recommendations by specialty, 23,[34][35][36]40,52,53 but several of these studies did not include pediatricians. 34,52,53 Most studies did not find variation in HPV vaccine recommendations by provider sex, 9,23,30,36,39,44,[47][48][49]54 but those that did most often favored female providers. 24,25,29,33,53 Similarly, most studies did not find variation in HPV vaccine recommendations by provider age or years in practice, 30,33,36,47,49 although a few did with mixed results.…”

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

“…52,63 Provider communication was consistently associated with patients' sex such that providers' recommendation intentions and behavior were more supportive of HPV vaccination for girls versus boys. 10,12,24,25,29,33,37,44,55,57,58,60,64,65 For example, the 2014 NIS-Teen found that 64% of age-eligible girls had received a provider recommendation compared to just 42% of boys. 10 All but one study examining patients' race/ethnicity suggested disparities in provider communication with parents of African American and Hispanic adolescents less often discussing HPV vaccine with a provider or receiving HPV recommendations than parents of non-Hispanic White adolescents.…”

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

See 4 more Smart Citations

Provider communication about HPV vaccination: A systematic review

Gilkey

McRee

2016

Human Vaccines & Immunotherapeutics

235

220

View full text Add to dashboard Cite

Background. Improving HPV vaccination coverage in the US will require healthcare providers to recommend the vaccine more effectively. To inform quality improvement efforts, we systematically reviewed studies of provider communication about HPV vaccination. Methods. We searched MEDLINE, CINAHL, EMBASE, and POPLINE in August 2015 to identify studies of provider communication about HPV vaccination. Results. We identified 101 qualitative and quantitative studies. Providers less often recommended HPV vaccine if they were uncomfortable discussing sex, perceived parents as hesitant, or believed patients to be low risk. Patients less often received recommendations if they were younger, male, or from racial/ethnic minorities. Despite parents' preference for unambiguous recommendations, providers often sent mixed messages by failing to endorse HPV vaccine strongly, differentiating it from other vaccines, and presenting it as an "optional" vaccine that could be delayed. Conclusion. Interventions are needed to help providers deliver effective recommendations in the complex communication environment surrounding HPV vaccination.

show abstract

Section: Preferences In Communication Source By Provider Typementioning

confidence: 83%

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

Section: Preferences In Communication Source By Provider Typementioning

confidence: 99%

See 3 more Smart Citations

Provider communication about HPV vaccination: A systematic review

Gilkey

McRee

2016

Human Vaccines & Immunotherapeutics

235

220

View full text Add to dashboard Cite

show abstract

Population Trends and Long-term Outlook for Oropharyngeal Cancer

Osazuwa‐Peters

Davies

2022

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

A decade ago, a seminal study in the oropharyngeal cancer field 1 reported that there had been a 225% increase in incidence of human papillomavirus (HPV)-associated oropharyngeal cancer in the US between 1988 and 2004. Crucially, the authors projected that if trends were to continue, HPV-positive oropharyngeal cancer would surpass cervical cancer as the leading HPVassociated cancer in the US by 2020. 1 This prediction has since become a reality. 2 Between 2012 and 2016, HPV-associated oropharyngeal cancer indeed became the most common HPV-associated cancer in the US, and its incidence has surpassed cervical cancer, the disease for which the HPV vaccine was first developed and marketed. 3,4 In this issue of JAMA Otolaryngology-Head & Neck Surgery, the crosssectional study by Damgacioglu and colleagues 5 shines light on the trends in oropharyngeal cancer since the turn of the millennium using a relatively newly publicly available source of national data. They report that oropharyngeal cancer incidence increased nationally in the US between 2001 and 2017, especially among older adults. 5 This study by Damgacioglu et al 5 encompasses the introduction of the HPV vaccine in 2006, first approved and marketed for use in girls and then formally recommended for boys starting in 2011. 6 While there are at least 12 oncogenic strains of HPV found in the mucosa, HPV-16 and HPV-18 account for about 95% of all HPV-positive oropharyngeal cancer, and both HPV types have been covered by all HPV vaccines since 2006, including bivalent, quadrivalent, and the nonavalent vaccines now currently used in the US. 7 Several studies have shown the benefits of the HPV vaccine in preventing cervical intraepithelial neoplasia and cervical cancer. 8,9 In contrast, there is currently no approved screening for oropharyngeal cancer, and there are no universally accepted precancer targets. Hence, the current guidelines accept oral HPV prevention as an acceptable surrogate for oropharyngeal cancer, and that is currently the only primary cancer prevention for HPV-associated oropharyngeal cancer. 10 Damgacioglu et al 5 suggest that the HPV vaccine may also be making a difference in oropharyngeal cancer incidence. Between 2001 and 2016, there was a decrease in oropharyngeal cancer incidence among young males. While there is reason to be excited about the prospect of a primary prevention of oropharyngeal cancer through HPV vaccination, this still probably remains in the more distant future. Based on recent modeling studies, a significantly increased incidence of oropharyngeal cancer is projected in the next 2 decades. 11 The effect of HPV vaccination on the incidence of oropharyngeal cancer through 2045 is anticipated to

show abstract